<p>Fulcrum Therapeutics, Inc. (NASDAQ:FULC - 获取免费报告) 的股价在周四的午盘交易中下跌了 5.7%，原因是内部人士出售股票。该股最低交易价为 12.56 美元，最后交易价为 13.0190 美元。在午盘交易中，约有 1,264,584 股易手，较平均每日交易量 732,198 股增加了 73%。该股此前收盘价为 13.80 美元。</p>
<p>获取 <strong>Fulcrum Therapeutics</strong> 的提醒：</p>
<p>具体来说，主要股东 Ra Capital Management, L.P. 于 12 月 8 日星期一出售了 4,175,139 股 Fulcrum Therapeutics 股票，交易的平均价格为 13.98 美元，总价值为 58,368,443.22 美元。出售完成后，内部人士持有该公司 6,053,960 股股票，估值约为 84,634,360.80 美元。这笔交易代表其持股比例减少了 40.82%。该出售在与 SEC 的法律文件中披露，您可以通过此超链接访问。</p>
<h2>分析师设定新目标价</h2>
<p>多家券商对 FULC 进行了评估。美国银行在周二的研究报告中将 Fulcrum Therapeutics 的目标价从 6.00 美元上调至 7.00 美元，并给予该股 “表现不佳” 的评级。华尔街 Zen 在 11 月 1 日星期六的研究报告中将 Fulcrum Therapeutics 的评级从 “持有” 下调至 “卖出”。加拿大皇家银行在周一将 Fulcrum Therapeutics 的目标价从 7.00 美元上调至 10.00 美元，并给予该公司 “行业表现” 的评级。高盛集团在周一重申了对 Fulcrum Therapeutics 股票的 “积极” 评级。最后，Leerink Partners 在 10 月 21 日的报告中设定了 Fulcrum Therapeutics 的目标价为 20.00 美元，并给予该股 “跑赢大盘” 的评级。一位分析师给予该股 “强烈买入” 评级，六位分析师给予 “买入” 评级，一位分析师给予 “持有” 评级，三位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，Fulcrum Therapeutics 的共识评级为 “持有”，平均目标价为 18.50 美元。</p>
<p><strong>获取我们关于 Fulcrum Therapeutics 的最新股票报告</strong></p>
<h2>Fulcrum Therapeutics 股票表现</h2>
<p>该股市值为 7.0345 亿美元，市盈率为-11.02，贝塔值为 3.17。该公司 50 日移动平均价格为 9.65 美元，200 日移动平均价格为 8.03 美元。</p>
<p>Fulcrum Therapeutics (NASDAQ:FULC - 获取免费报告) 最近于 10 月 29 日星期三发布了季度财报。公司报告每股收益为-0.31 美元，低于分析师的共识预期-0.29 美元，差额为-0.02 美元。研究分析师平均预测 Fulcrum Therapeutics, Inc. 本年度每股收益为-0.16 美元。</p>
<h2>机构投资者对 Fulcrum Therapeutics 的看法</h2>
<p>多家对冲基金最近增持或减持了 FULC 的股份。Quarry LP 在第三季度购买了 Fulcrum Therapeutics 的新股份，价值 35,000 美元。Farther Finance Advisors LLC 在第三季度增持了 Fulcrum Therapeutics 的持股，增幅为 108.3%。Farther Finance Advisors LLC 目前持有该公司 7,112 股股票，价值 65,000 美元，在此期间又购买了 3,697 股。Russell Investments Group Ltd. 在第二季度增持了 Fulcrum Therapeutics 的股份，增幅为 4,209.3%。Russell Investments Group Ltd. 目前持有该公司 9,308 股股票，价值 64,000 美元，在上个季度又购买了 9,092 股。Assetmark Inc. 在第三季度购买了 Fulcrum Therapeutics 的新股份，估值约为 88,000 美元。最后，Jump Financial LLC 在第一季度购买了 Fulcrum Therapeutics 的新股份，估值约为 30,000 美元。目前 89.83% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>关于 Fulcrum Therapeutics</h2>
<p>(获取免费报告)</p>
<p>Fulcrum Therapeutics, Inc. 是一家临床阶段的生物制药公司，专注于开发产品以改善美国基因定义疾病患者的生活，特别是在医疗需求高的领域。其产品候选者包括 losmapimod，一种用于治疗面肩肱肌肉萎缩症的小分子，目前处于第三阶段临床试验；以及 pociredir，一种用于治疗镰状细胞病和β-地中海贫血的胎儿血红蛋白诱导剂，目前处于第一阶段临床试验。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，胜过 Fulcrum Therapeutics</li>
<li>现在值得购买的 2 只金融科技股票和 1 只应避免的股票</li>
<li>2026 年反弹选择：3 只标普滞后股有望突破</li>
<li>如何最有效地使用 MarketBeat 盈利筛选器</li>
<li>特斯拉多头看到 500 美元的前景——但空头警告可能会出现痛苦的反转</li>
<li>比较和交易高市盈率股票</li>
<li>错过了 NVIDIA？Braze 可能是下一个 AI 股票突破</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Fulcrum Therapeutics 吗？</h2>
<p>在考虑 Fulcrum Therapeutics 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Fulcrum Therapeutics 并不在名单上。</p>
<p>虽然 Fulcrum Therapeutics 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

FULC

<p>Fulcrum Therapeutics 的股票在主要股东 Ra Capital Management 出售 417 万股后下跌了 5.7%。该股票交易价格为 13.0190 美元，较 13.80 美元下跌，交易量有所增加。分析师的评级不一，普遍持 “持有” 意见，平均目标价为 18.50 美元。机构投资者持有 89.83% 的股份。Fulcrum 专注于针对基因定义疾病的治疗，相关产品正在进行临床试验</p>

<p>Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report)'s share price was down 5.7% during mid-day trading on Thursday following insider selling activity. The stock traded as low as $12.56 and last traded at $13.0190. Approximately 1,264,584 shares changed hands during mid-day trading, an increase of 73% from the average daily volume of 732,198 shares. The stock had previously closed at $13.80.</p>
<div class="lb-trans"><p>Fulcrum Therapeutics, Inc. (NASDAQ:FULC - 获取免费报告) 的股价在周四的午盘交易中下跌了 5.7%，原因是内部人士出售股票。该股最低交易价为 12.56 美元，最后交易价为 13.0190 美元。在午盘交易中，约有 1,264,584 股易手，较平均每日交易量 732,198 股增加了 73%。该股此前收盘价为 13.80 美元。</p>
</div><p>Get <strong>Fulcrum Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Fulcrum Therapeutics</strong> 的提醒：</p>
</div><p>Specifically, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of Fulcrum Therapeutics stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $13.98, for a total value of $58,368,443.22. Following the completion of the sale, the insider owned 6,053,960 shares of the company's stock, valued at approximately $84,634,360.80. This trade represents a 40.82% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.</p>
<div class="lb-trans"><p>具体来说，主要股东 Ra Capital Management, L.P. 于 12 月 8 日星期一出售了 4,175,139 股 Fulcrum Therapeutics 股票，交易的平均价格为 13.98 美元，总价值为 58,368,443.22 美元。出售完成后，内部人士持有该公司 6,053,960 股股票，估值约为 84,634,360.80 美元。这笔交易代表其持股比例减少了 40.82%。该出售在与 SEC 的法律文件中披露，您可以通过此超链接访问。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>A number of brokerages have weighed in on FULC. Bank of America boosted their price target on shares of Fulcrum Therapeutics from $6.00 to $7.00 and gave the stock an &#34;underperform&#34; rating in a research note on Tuesday. Wall Street Zen lowered shares of Fulcrum Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, November 1st. Royal Bank Of Canada increased their target price on Fulcrum Therapeutics from $7.00 to $10.00 and gave the company a &#34;sector perform&#34; rating in a research note on Monday. The Goldman Sachs Group reaffirmed a &#34;positive&#34; rating on shares of Fulcrum Therapeutics in a research note on Monday. Finally, Leerink Partners set a $20.00 price objective on Fulcrum Therapeutics and gave the stock an &#34;outperform&#34; rating in a report on Tuesday, October 21st. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, Fulcrum Therapeutics has a consensus rating of &#34;Hold&#34; and an average target price of $18.50.</p>
<div class="lb-trans"><p>多家券商对 FULC 进行了评估。美国银行在周二的研究报告中将 Fulcrum Therapeutics 的目标价从 6.00 美元上调至 7.00 美元，并给予该股 “表现不佳” 的评级。华尔街 Zen 在 11 月 1 日星期六的研究报告中将 Fulcrum Therapeutics 的评级从 “持有” 下调至 “卖出”。加拿大皇家银行在周一将 Fulcrum Therapeutics 的目标价从 7.00 美元上调至 10.00 美元，并给予该公司 “行业表现” 的评级。高盛集团在周一重申了对 Fulcrum Therapeutics 股票的 “积极” 评级。最后，Leerink Partners 在 10 月 21 日的报告中设定了 Fulcrum Therapeutics 的目标价为 20.00 美元，并给予该股 “跑赢大盘” 的评级。一位分析师给予该股 “强烈买入” 评级，六位分析师给予 “买入” 评级，一位分析师给予 “持有” 评级，三位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，Fulcrum Therapeutics 的共识评级为 “持有”，平均目标价为 18.50 美元。</p>
</div><p><strong>Get Our Latest Stock Report on Fulcrum Therapeutics</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Fulcrum Therapeutics 的最新股票报告</strong></p>
</div><h2>Fulcrum Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Fulcrum Therapeutics 股票表现</h2>
</div><p>The stock has a market cap of $703.45 million, a P/E ratio of -11.02 and a beta of 3.17. The firm has a 50-day moving average price of $9.65 and a 200-day moving average price of $8.03.</p>
<div class="lb-trans"><p>该股市值为 7.0345 亿美元，市盈率为-11.02，贝塔值为 3.17。该公司 50 日移动平均价格为 9.65 美元，200 日移动平均价格为 8.03 美元。</p>
</div><p>Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last posted its quarterly earnings data on Wednesday, October 29th. The company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.02). On average, research analysts predict that Fulcrum Therapeutics, Inc. will post -0.16 earnings per share for the current year.</p>
<div class="lb-trans"><p>Fulcrum Therapeutics (NASDAQ:FULC - 获取免费报告) 最近于 10 月 29 日星期三发布了季度财报。公司报告每股收益为-0.31 美元，低于分析师的共识预期-0.29 美元，差额为-0.02 美元。研究分析师平均预测 Fulcrum Therapeutics, Inc. 本年度每股收益为-0.16 美元。</p>
</div><h2>Institutional Investors Weigh In On Fulcrum Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Fulcrum Therapeutics 的看法</h2>
</div><p>A number of hedge funds have recently added to or reduced their stakes in FULC. Quarry LP purchased a new stake in shares of Fulcrum Therapeutics in the third quarter worth $35,000. Farther Finance Advisors LLC boosted its holdings in Fulcrum Therapeutics by 108.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 7,112 shares of the company's stock worth $65,000 after buying an additional 3,697 shares during the period. Russell Investments Group Ltd. increased its stake in Fulcrum Therapeutics by 4,209.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company's stock worth $64,000 after buying an additional 9,092 shares in the last quarter. Assetmark Inc. bought a new stake in Fulcrum Therapeutics during the third quarter valued at about $88,000. Finally, Jump Financial LLC purchased a new position in shares of Fulcrum Therapeutics in the first quarter valued at about $30,000. 89.83% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>多家对冲基金最近增持或减持了 FULC 的股份。Quarry LP 在第三季度购买了 Fulcrum Therapeutics 的新股份，价值 35,000 美元。Farther Finance Advisors LLC 在第三季度增持了 Fulcrum Therapeutics 的持股，增幅为 108.3%。Farther Finance Advisors LLC 目前持有该公司 7,112 股股票，价值 65,000 美元，在此期间又购买了 3,697 股。Russell Investments Group Ltd. 在第二季度增持了 Fulcrum Therapeutics 的股份，增幅为 4,209.3%。Russell Investments Group Ltd. 目前持有该公司 9,308 股股票，价值 64,000 美元，在上个季度又购买了 9,092 股。Assetmark Inc. 在第三季度购买了 Fulcrum Therapeutics 的新股份，估值约为 88,000 美元。最后，Jump Financial LLC 在第一季度购买了 Fulcrum Therapeutics 的新股份，估值约为 30,000 美元。目前 89.83% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>About Fulcrum Therapeutics</h2>
<div class="lb-trans"><h2>关于 Fulcrum Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.</p>
<div class="lb-trans"><p>Fulcrum Therapeutics, Inc. 是一家临床阶段的生物制药公司，专注于开发产品以改善美国基因定义疾病患者的生活，特别是在医疗需求高的领域。其产品候选者包括 losmapimod，一种用于治疗面肩肱肌肉萎缩症的小分子，目前处于第三阶段临床试验；以及 pociredir，一种用于治疗镰状细胞病和β-地中海贫血的胎儿血红蛋白诱导剂，目前处于第一阶段临床试验。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Fulcrum Therapeutics</li>
<li>2 Fintech Stocks to Buy Now and 1 to Avoid</li>
<li>2026 Comeback Picks: 3 S&amp;P Laggards Poised to Break Out</li>
<li>How to Most Effectively Use the MarketBeat Earnings Screener</li>
<li>Tesla Bulls See $500 Ahead—But Bears Warn of a Painful Reversal</li>
<li>Comparing and Trading High PE Ratio Stocks</li>
<li>Missed NVIDIA? Braze Might Be the Next AI Stock Breakout</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Fulcrum Therapeutics</li>
<li>现在值得购买的 2 只金融科技股票和 1 只应避免的股票</li>
<li>2026 年反弹选择：3 只标普滞后股有望突破</li>
<li>如何最有效地使用 MarketBeat 盈利筛选器</li>
<li>特斯拉多头看到 500 美元的前景——但空头警告可能会出现痛苦的反转</li>
<li>比较和交易高市盈率股票</li>
<li>错过了 NVIDIA？Braze 可能是下一个 AI 股票突破</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Fulcrum Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Fulcrum Therapeutics 吗？</h2>
</div><p>Before you consider Fulcrum Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Fulcrum Therapeutics 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fulcrum Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Fulcrum Therapeutics 并不在名单上。</p>
</div><p>While Fulcrum Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Fulcrum Therapeutics 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Fulcrum Therapeutics (NASDAQ:FULC) 的股价在内部人士出售股票后下跌了 5.7%